Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Skin And Soft Tissue Infections-Pipeline Review, H1 2015

Skin And Soft Tissue Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Skin And Soft Tissue Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Skin And Soft Tissue Infections-Pipeline Review, H1 2015', provides an overview of the Skin And Soft Tissue Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Skin And Soft Tissue Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Skin And Soft Tissue Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Skin And Soft Tissue Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Skin And Soft Tissue Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Skin And Soft Tissue Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Skin And Soft Tissue Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Skin And Soft Tissue Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Skin And Soft Tissue Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Skin And Soft Tissue Infections Overview 10

Therapeutics Development 11

Pipeline Products for Skin And Soft Tissue Infections-Overview 11

Pipeline Products for Skin And Soft Tissue Infections-Comparative Analysis 12

Skin And Soft Tissue Infections-Therapeutics under Development by Companies 13

Skin And Soft Tissue Infections-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Skin And Soft Tissue Infections-Products under Development by Companies 20

Skin And Soft Tissue Infections-Companies Involved in Therapeutics Development 22

Allergan Plc 22

Atox Bio Inc. 23

Cempra, Inc. 24

CorMedix, Inc. 25

CrystalGenomics, Inc. 26

Debiopharm International S.A. 27

Dong-A Socio Group 28

GlaxoSmithKline Plc 29

Melinta Therapeutics, Inc 30

MicuRx Pharmaceuticals, Inc. 31

Motif Bio Plc 32

Nabriva Therapeutics AG 33

NovaDigm Therapeutics, Inc. 34

Phosphagenics Limited 35

Takeda Pharmaceutical Company Limited 36

Tetraphase Pharmaceuticals Inc. 37

The Medicines Company 38

Wockhardt Limited 39

Skin And Soft Tissue Infections-Therapeutics Assessment 40

Assessment by Monotherapy Products 40

Assessment by Target 41

Assessment by Mechanism of Action 43

Assessment by Route of Administration 45

Assessment by Molecule Type 47

Drug Profiles 49

AB-103-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

acorafloxacin hydrochloride-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

BC-7013-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

ceftaroline fosamil-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

CG-400549-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

CRMD-004-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Debio-1450-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Debio-1452-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

delafloxacin-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

eravacycline-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

fusidic acid-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

gepotidacin mesylate-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

iclaprim mesylate-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

IOG-101-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

KBP-7072-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

lefamulin-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

MRX-I-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Mul-1867-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

NDV-3-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Nu-2-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

oritavancin diphosphate-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

radezolid-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

siderocillin-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

Small Molecule for Skin Infections-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

Small Molecules to Inhibit DHFR for Infectious Diseases-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

tedizolid phosphate-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

VAL-301-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

WCK-2349-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Skin And Soft Tissue Infections-Recent Pipeline Updates 97

Skin And Soft Tissue Infections-Dormant Projects 126

Skin And Soft Tissue Infections-Discontinued Products 128

Skin And Soft Tissue Infections-Product Development Milestones 129

Featured News & Press Releases 129

Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority 129

Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections 129

Aug 05, 2014: Cubist's Once-daily SIVEXTRO (tedizolid phosphate) Available for Physician and Hospital Order in I.V. and Oral Formulations 130

Mar 31, 2014: FDA Advisory Committee Unanimously Recommends Approval of Cubist's SIVEXTRO (Tedizolid Phosphate) as Treatment for Serious Skin Infections 131

Feb 27, 2014: Cubist Announces EMA Acceptance of Tedizolid Marketing Authorization Application for Review 132

Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial 132

Sep 10, 2012: Atox Bio's AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections 133

Oct 25, 2011: Atox Bio Receives Orphan Drug Designation For AB103 For Treatment Of Necrotizing Soft Tissue Infections 134

May 05, 2011: Furiex To Present Two Abstracts Featuring JNJ-Q2 At Joint Meeting Of ECCMID And ICC 134

Oct 15, 2010: Cempra To Present New Data On TAKSTA At Annual Meeting Of Infectious Diseases Society Of America 135

Appendix 136

Methodology 136

Coverage 136

Secondary Research 136

Primary Research 136

Expert Panel Validation 136

Contact Us 136

Disclaimer 137

List of Tables

Number of Products under Development for Skin And Soft Tissue Infections, H1 2015 11

Number of Products under Development for Skin And Soft Tissue Infections-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Development, H1 2015 18

Comparative Analysis by Unknown Stage Development, H1 2015 19

Products under Development by Companies, H1 2015 20

Products under Development by Companies, H1 2015 (Contd..1) 21

Skin And Soft Tissue Infections-Pipeline by Allergan Plc, H1 2015 22

Skin And Soft Tissue Infections-Pipeline by Atox Bio Inc., H1 2015 23

Skin And Soft Tissue Infections-Pipeline by Cempra, Inc., H1 2015 24

Skin And Soft Tissue Infections-Pipeline by CorMedix, Inc., H1 2015 25

Skin And Soft Tissue Infections-Pipeline by CrystalGenomics, Inc., H1 2015 26

Skin And Soft Tissue Infections-Pipeline by Debiopharm International S.A., H1 2015 27

Skin And Soft Tissue Infections-Pipeline by Dong-A Socio Group, H1 2015 28

Skin And Soft Tissue Infections-Pipeline by GlaxoSmithKline Plc, H1 2015 29

Skin And Soft Tissue Infections-Pipeline by Melinta Therapeutics, Inc, H1 2015 30

Skin And Soft Tissue Infections-Pipeline by MicuRx Pharmaceuticals, Inc., H1 2015 31

Skin And Soft Tissue Infections-Pipeline by Motif Bio Plc, H1 2015 32

Skin And Soft Tissue Infections-Pipeline by Nabriva Therapeutics AG, H1 2015 33

Skin And Soft Tissue Infections-Pipeline by NovaDigm Therapeutics, Inc., H1 2015 34

Skin And Soft Tissue Infections-Pipeline by Phosphagenics Limited, H1 2015 35

Skin And Soft Tissue Infections-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 36

Skin And Soft Tissue Infections-Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 37

Skin And Soft Tissue Infections-Pipeline by The Medicines Company, H1 2015 38

Skin And Soft Tissue Infections-Pipeline by Wockhardt Limited, H1 2015 39

Assessment by Monotherapy Products, H1 2015 40

Number of Products by Stage and Target, H1 2015 42

Number of Products by Stage and Mechanism of Action, H1 2015 44

Number of Products by Stage and Route of Administration, H1 2015 46

Number of Products by Stage and Molecule Type, H1 2015 48

Skin And Soft Tissue Infections Therapeutics-Recent Pipeline Updates, H1 2015 97

Skin And Soft Tissue Infections-Dormant Projects, H1 2015 126

Skin And Soft Tissue Infections-Dormant Projects (Contd..1), H1 2015 127

Skin And Soft Tissue Infections-Discontinued Products, H1 2015 128

List of Figures

Number of Products under Development for Skin And Soft Tissue Infections, H1 2015 11

Number of Products under Development for Skin And Soft Tissue Infections-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Products, H1 2015 18

Assessment by Monotherapy Products, H1 2015 40

Number of Products by Top 10 Targets, H1 2015 41

Number of Products by Stage and Top 10 Targets, H1 2015 41

Number of Products by Top 10 Mechanism of Actions, H1 2015 43

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 43

Number of Products by Top 10 Routes of Administration, H1 2015 45

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 45

Number of Products by Top 10 Molecule Types, H1 2015 47

Number of Products by Stage and Top 10 Molecule Types, H1 2015 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Allergan Plc

Atox Bio Inc.

Cempra, Inc.

CorMedix, Inc.

CrystalGenomics, Inc.

Debiopharm International S.A.

Dong-A Socio Group

GlaxoSmithKline Plc

Melinta Therapeutics, Inc

MicuRx Pharmaceuticals, Inc.

Motif Bio Plc

Nabriva Therapeutics AG

NovaDigm Therapeutics, Inc.

Phosphagenics Limited

Takeda Pharmaceutical Company Limited

Tetraphase Pharmaceuticals Inc.

The Medicines Company

Wockhardt Limited

Skin And Soft Tissue Infections Therapeutic Products under Development, Key Players in Skin And Soft Tissue Infections Therapeutics, Skin And Soft Tissue Infections Pipeline Overview, Skin And Soft Tissue Infections Pipeline, Skin And Soft Tissue Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com